Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C14H16N2O3.ClH |
| Molecular Weight | 296.749 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.ONC(=N)CC(O)COC1=C2C=CC=CC2=CC=C1
InChI
InChIKey=QMIHLTWUCXXBQQ-UHFFFAOYSA-N
InChI=1S/C14H16N2O3.ClH/c15-14(16-18)8-11(17)9-19-13-7-3-5-10-4-1-2-6-12(10)13;/h1-7,11,17-18H,8-9H2,(H2,15,16);1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C14H16N2O3 |
| Molecular Weight | 260.2884 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Kinetic resolution of 1-chloro-3-(1-naphthyloxy)-2-propanol, an intermediate in the synthesis of beta-adrenergic receptor blockers. | 2003-06 |
|
| [Acute nadoxolol poisoning. A multicentric study of 35 cases]. | 1982-05 |
|
| [Clinical study of a new anti-arrhythmia agent: nadoxolol]. | 1976-04 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugfuture.com/chemdata/nadoxolol.html
LD50 in mice (mg/kg): 180 i.v.; 1000 orally
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:14:01 GMT 2025
by
admin
on
Mon Mar 31 20:14:01 GMT 2025
|
| Record UNII |
RZ9G589EN2
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
35991-93-6
Created by
admin on Mon Mar 31 20:14:01 GMT 2025 , Edited by admin on Mon Mar 31 20:14:01 GMT 2025
|
PRIMARY | |||
|
88709809
Created by
admin on Mon Mar 31 20:14:01 GMT 2025 , Edited by admin on Mon Mar 31 20:14:01 GMT 2025
|
PRIMARY | |||
|
236178
Created by
admin on Mon Mar 31 20:14:01 GMT 2025 , Edited by admin on Mon Mar 31 20:14:01 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID10957415
Created by
admin on Mon Mar 31 20:14:01 GMT 2025 , Edited by admin on Mon Mar 31 20:14:01 GMT 2025
|
PRIMARY | |||
|
m1212
Created by
admin on Mon Mar 31 20:14:01 GMT 2025 , Edited by admin on Mon Mar 31 20:14:01 GMT 2025
|
PRIMARY | Merck Index | ||
|
252-825-2
Created by
admin on Mon Mar 31 20:14:01 GMT 2025 , Edited by admin on Mon Mar 31 20:14:01 GMT 2025
|
PRIMARY | |||
|
RZ9G589EN2
Created by
admin on Mon Mar 31 20:14:01 GMT 2025 , Edited by admin on Mon Mar 31 20:14:01 GMT 2025
|
PRIMARY | |||
|
SUB03370MIG
Created by
admin on Mon Mar 31 20:14:01 GMT 2025 , Edited by admin on Mon Mar 31 20:14:01 GMT 2025
|
PRIMARY | |||
|
100000085705
Created by
admin on Mon Mar 31 20:14:01 GMT 2025 , Edited by admin on Mon Mar 31 20:14:01 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE | |||
|
|
PARENT -> SALT/SOLVATE |